HOME >> BIOLOGY >> NEWS
Penn researchers discover how key protein stops inflammation

mmatory response, says Chen. Bcl-3 appears to take in information from the body and, in response to infection, interferes with p50 degradation to decrease inflammatory response.

Inflammation is natural, says Chen. If we didnt respond to infectious agents, bacteria would kill us. However, the inflammatory response must be controlled or we could also die. Bcl-3 helps regulate inflammation.

By using what we now know about Bcl-3 regulatory function, we hope to create new ways to control inflammation for therapeutic purposes with selective anti-inflammatory agents, says Carmody.

Although drugs to suppress inflammation currently exist, Chen and Carmody say they cause many undesirable side effects in patients with inflammatory diseases.

Current drug treatments target inflammation signaling pathways. When you inhibit entire pathways, you can produce negative side effects, said Carmody. Since Bcl-3 acts on specific genes, we should be able to target a subset of dangerous regulatory genes without disrupting other important immune responses. Such drugs could benefit patients with chronic inflammation and transplant recipients as well as those suffering with inflammatory diseases.

In the future, the scientists aim to determine the components of the cell responsible for flagging p50 for destruction and instructing Bcl-3 to perform its vital function.


'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
7-Aug-2007


Page: 1 2

Related biology news :

1. Innovative tagging technique may help researchers better protect fish stocks
2. ASU researchers partner with UOP to make biofuel for military jets a reality
3. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
4. Penn researchers discover pathway that eliminates genetic defects in red blood cells
5. U-M researchers find family of on switches that cause prostate cancer
6. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
7. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
8. MGH researchers confirm that bone marrow restores fertility in female mice
9. Smithsonians National Zoo researchers use electronic eggs to help save threatened species
10. U-M researchers identify gene involved in breast cancer
11. Drug protects brain cells in Huntingtons disease model, researchers find

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Penn researchers discover how key protein stops inflammation

(Date:5/21/2013)... the nation,s land and water resources could likely support ... 25 billion gallons of algae-based fuel a year in ... , The findings come from an in-depth look at ... significant amounts of algae in large, specially built shallow ... issue of Environmental Science and Technology , published ...
(Date:5/21/2013)... a class of pharmaceuticals can both prevent and treat ... as "TSPO ligands," are currently used for certain types ... TSPO ligand in young adult mice when pathology was ... pathology was quite severe," said lead researcher Christian Pike ... reduced measures of pathology and improved behavior at both ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: